Cargando…

Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?

SIMPLE SUMMARY: Almost 20% of patients with a locally advanced oesophageal cancer presented long-term local control after exclusive chemoradiotherapy (CRT) and could potentially avoid surgery and its morbidity and mortality. With the aim of identifying the patients that would present long-term locor...

Descripción completa

Detalles Bibliográficos
Autores principales: De Bari, Berardino, Lefevre, Loriane, Henriques, Julie, Gatta, Roberto, Falcoz, Antoine, Mathieu, Pierre, Borg, Christophe, Dinapoli, Nicola, Boulahdour, Hatem, Boldrini, Luca, Valentini, Vincenzo, Vernerey, Dewi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406583/
https://www.ncbi.nlm.nih.gov/pubmed/36011035
http://dx.doi.org/10.3390/cancers14164043
_version_ 1784774156714246144
author De Bari, Berardino
Lefevre, Loriane
Henriques, Julie
Gatta, Roberto
Falcoz, Antoine
Mathieu, Pierre
Borg, Christophe
Dinapoli, Nicola
Boulahdour, Hatem
Boldrini, Luca
Valentini, Vincenzo
Vernerey, Dewi
author_facet De Bari, Berardino
Lefevre, Loriane
Henriques, Julie
Gatta, Roberto
Falcoz, Antoine
Mathieu, Pierre
Borg, Christophe
Dinapoli, Nicola
Boulahdour, Hatem
Boldrini, Luca
Valentini, Vincenzo
Vernerey, Dewi
author_sort De Bari, Berardino
collection PubMed
description SIMPLE SUMMARY: Almost 20% of patients with a locally advanced oesophageal cancer presented long-term local control after exclusive chemoradiotherapy (CRT) and could potentially avoid surgery and its morbidity and mortality. With the aim of identifying the patients that would present long-term locoregional control, we analysed in this study the potential of some pre-treatment positron-emission tomography-computed tomography (PET-CT)-based features in predicting long-term responses and local control in patients treated with definitive CRT. Our results show that radiomics allows for the identification of patients with long-term locoregional control. If confirmed on larger populations, our results could allow the identification of patients who are good responders to CRT, and who could potentially avoid surgery. ABSTRACT: Background: We evaluated the value of pre-treatment positron-emission tomography–computed tomography (PET-CT)-based radiomic features in predicting the locoregional progression-free survival (LR-PFS) of patients with inoperable or unresectable oesophageal cancer. Material and Methods: Forty-six patients were included and 230 radiomic parameters were extracted. After a principal component analysis (PCA), we identified the more robust radiomic parameters, and we used them to develop a heatmap. Finally, we correlated these radiomic features with LR-PFS. Results: The median follow-up time was 17 months. The two-year LR-PFS and PFS rates were 35.9% (95% CI: 18.9–53.3) and 21.6% (95%CI: 10.0–36.2), respectively. After the correlation analysis, we identified 55 radiomic parameters that were included in the heatmap. According to the results of the hierarchical clustering, we identified two groups of patients presenting statistically different median LR-PFSs (22.8 months vs. 9.9 months; HR = 2.64; 95% CI 0.97–7.15; p = 0.0573). We also identified two radiomic features (“F_rlm_rl_entr_per” and “F_rlm_2_5D_rl_entr”) significantly associated with LR-PFS. Patients expressing a “F_rlm_2_5D_rl_entr” of <3.3 had a better median LR- PFS (29.4 months vs. 8.2 months; p = 0.0343). Patients presenting a “F_rlm_rl_entr_per” of <4.7 had a better median LR-PFS (50.4 months vs. 9.9 months; p = 0.0132). Conclusion: We identified two radiomic signatures associated with a lower risk of locoregional relapse after CRT.
format Online
Article
Text
id pubmed-9406583
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94065832022-08-26 Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer? De Bari, Berardino Lefevre, Loriane Henriques, Julie Gatta, Roberto Falcoz, Antoine Mathieu, Pierre Borg, Christophe Dinapoli, Nicola Boulahdour, Hatem Boldrini, Luca Valentini, Vincenzo Vernerey, Dewi Cancers (Basel) Article SIMPLE SUMMARY: Almost 20% of patients with a locally advanced oesophageal cancer presented long-term local control after exclusive chemoradiotherapy (CRT) and could potentially avoid surgery and its morbidity and mortality. With the aim of identifying the patients that would present long-term locoregional control, we analysed in this study the potential of some pre-treatment positron-emission tomography-computed tomography (PET-CT)-based features in predicting long-term responses and local control in patients treated with definitive CRT. Our results show that radiomics allows for the identification of patients with long-term locoregional control. If confirmed on larger populations, our results could allow the identification of patients who are good responders to CRT, and who could potentially avoid surgery. ABSTRACT: Background: We evaluated the value of pre-treatment positron-emission tomography–computed tomography (PET-CT)-based radiomic features in predicting the locoregional progression-free survival (LR-PFS) of patients with inoperable or unresectable oesophageal cancer. Material and Methods: Forty-six patients were included and 230 radiomic parameters were extracted. After a principal component analysis (PCA), we identified the more robust radiomic parameters, and we used them to develop a heatmap. Finally, we correlated these radiomic features with LR-PFS. Results: The median follow-up time was 17 months. The two-year LR-PFS and PFS rates were 35.9% (95% CI: 18.9–53.3) and 21.6% (95%CI: 10.0–36.2), respectively. After the correlation analysis, we identified 55 radiomic parameters that were included in the heatmap. According to the results of the hierarchical clustering, we identified two groups of patients presenting statistically different median LR-PFSs (22.8 months vs. 9.9 months; HR = 2.64; 95% CI 0.97–7.15; p = 0.0573). We also identified two radiomic features (“F_rlm_rl_entr_per” and “F_rlm_2_5D_rl_entr”) significantly associated with LR-PFS. Patients expressing a “F_rlm_2_5D_rl_entr” of <3.3 had a better median LR- PFS (29.4 months vs. 8.2 months; p = 0.0343). Patients presenting a “F_rlm_rl_entr_per” of <4.7 had a better median LR-PFS (50.4 months vs. 9.9 months; p = 0.0132). Conclusion: We identified two radiomic signatures associated with a lower risk of locoregional relapse after CRT. MDPI 2022-08-22 /pmc/articles/PMC9406583/ /pubmed/36011035 http://dx.doi.org/10.3390/cancers14164043 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Bari, Berardino
Lefevre, Loriane
Henriques, Julie
Gatta, Roberto
Falcoz, Antoine
Mathieu, Pierre
Borg, Christophe
Dinapoli, Nicola
Boulahdour, Hatem
Boldrini, Luca
Valentini, Vincenzo
Vernerey, Dewi
Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
title Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
title_full Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
title_fullStr Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
title_full_unstemmed Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
title_short Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?
title_sort could 18-fdg pet-ct radiomic features predict the locoregional progression-free survival in inoperable or unresectable oesophageal cancer?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406583/
https://www.ncbi.nlm.nih.gov/pubmed/36011035
http://dx.doi.org/10.3390/cancers14164043
work_keys_str_mv AT debariberardino could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT lefevreloriane could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT henriquesjulie could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT gattaroberto could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT falcozantoine could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT mathieupierre could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT borgchristophe could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT dinapolinicola could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT boulahdourhatem could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT boldriniluca could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT valentinivincenzo could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer
AT vernereydewi could18fdgpetctradiomicfeaturespredictthelocoregionalprogressionfreesurvivalininoperableorunresectableoesophagealcancer